Losartan + Sunitinib in Treatment of Osteosarcoma

This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.

Trial Details

NCT ID
NCT03900793
Phase
PHASE1
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Losartan
  • Sunitinib
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • 1\. Provision to sign and date the consent form (if individual is a minor, provision of a parent or legal guardian to sign and date the consent for…
  • 2\. Stated willingness to comply with all study procedures and be available for the duration of the study.
  • 3\. Male or female aged ≥ 10 years old. 4. Histologically confirmed osteosarcoma (at either original diagnosis or relapse) that has either recurred…
  • Patients with surface or periosteal osteosarcoma are not eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →